Johnson & Johnson (JNJ) announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.While one sBLA seeks approval of Tremfya for treating children 6 years and older with moderate-to-severe plaque psoriasis (PsO), the other one is for children 5 years of age and older with active juvenile psoriatic arthritis (jPsA).Tremfya, an IL-23 inhibitor, is already approved to treat certain adult patients with plaque psoriasis and act ...